 The following article is sponsored by Skye Bioscience, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. The beginning of 2021 marked the start of a busy time for cannabinoid biopharmaceutical company Skye Bioscience, Inc. OTC: SKYE, not the least of which is the companys transition from its previous name, Emerald Biosciences, to its new and ambitious imprimatur. 